Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global E Online Ltd (GLBE) vs TransMedics Group Inc (TMDX) Price & Performance

Global E Online LtdTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

Global E Online Ltd vs TransMedics Group Inc — how do they compare? Global E Online Ltd trades at $39.85 (market cap $6.87B), while TransMedics Group Inc trades at $87.2 (market cap $3.10B). The key difference: Global E Online Ltd is far larger — about 2.2× TransMedics Group Inc's market cap, and Global E Online Ltd is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.

GLBETMDX
Market Cap
$6.87B$3.10B
Sector
TechnologyTechnology
52-Week High
$42.32$150.42
52-Week Low
$27.54$61.99
Enterprise Value
$6.34B$3.49B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global E Online Ltd

GLBE trades at $42.08, up 2.26% today and near its 52-week high, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 results, beating EPS expectations and raising full-year guidance, driven by 39% revenue growth and expanded EBITDA margins. Analyst consensus is unanimously bullish with a $44.75 price target, reflecting confidence in its e-commerce enablement platform.

The stock offers upside potential from robust growth and strategic acquisitions like Passport, but risks include high valuation multiples (P/E of 61.06) and insider selling. Execution on raised guidance and integration of new logistics capabilities are key to sustaining momentum amid competitive pressures.

TransMedics Group Inc

TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.

Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Global E Online Ltd

Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.

Read more on GLBE

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX